August 17, 2017

Direct providership by American Academy of Addiction Psychiatry

Adam Bisaga, MD | Professor of Psychiatry, Columbia University Medical Center, New York, NY

View the Module

Module Description
The first module presents background information on the use of opioid antagonists in treatment of OUD. It describes the clinical pharmacology of naltrexone and its mechanism of therapeutic effect, the differences between agonist and antagonist based treatment, the development of various preparations of naltrexone and highlights the available evidence for its efficacy.

Educational Objectives

  • Discuss the pharmacology of medications used in treatment of opioid use disorder (OUD)
  • Appraise the differences between agonist and antagonist-based treatment of OUD
  • Describe the evolution of antagonist-based treatment for opioid dependence
  • Evaluate the evidence for efficacy of naltrexone in treatment of OUD

Accreditation Statement 
American Academy of Addiction Psychiatry (AAAP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement
American Academy of Addiction Psychiatry (AAAP) designates this enduring material for a maximum of 1 (one) AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

PA Accreditation
PAs may claim a maximum of 1 Category 1 credit for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Method of participation in the learning process
In order to receive a maximum of 1 AMA PRA Category 1 Credit™, participants must participate in the entire module, answer post-test questions, pass with a 70% pass rate and complete an evaluation at the end of the activity.